Baxter International, Inc. (NYSE:BAX)

CAPS Rating: 5 out of 5

The Company provides medical products and services. Its medical devices, pharmaceuticals and biotechnology assists healthcare professionals and their patients in the treatment of complex medical conditions.

Results 1 - 20 of 82 : 1 2 3 4 5 Next »

Recs

0
Member Avatar gonelong (41.01) Submitted: 6/18/2015 4:00:54 PM : Outperform Start Price: $37.45 BAX Score: +9.62

DG50: http://seekingalpha.com/article/2764265-its-new-its-nifty-its-the-dividend-growth-50

Recs

0
Member Avatar pupowski (< 20) Submitted: 5/5/2015 7:56:55 PM : Outperform Start Price: $37.51 BAX Score: +8.62

well managed

Recs

0
Member Avatar MKBooie2004 (< 20) Submitted: 3/16/2014 3:13:11 PM : Outperform Start Price: $34.56 BAX Score: +5.21

Safe Haven Health Care with a increasing sustainable dividend. At my age slow gain is much better than no gain.

Recs

0
Member Avatar nicholas13 (56.77) Submitted: 1/17/2014 12:09:06 AM : Outperform Start Price: $36.18 BAX Score: -0.66

Solid business model, company culture lends itself to more innovation. One of the major players if not the company to beat in renal healthcare.

Recs

2
Member Avatar JohnCLeven (52.74) Submitted: 1/4/2014 12:28:25 PM : Outperform Start Price: $34.53 BAX Score: +0.85

Over the past 20 years, BAX has averaged ROE of 23%, and that average has been consistently increasing. (It was 34% last year) BAX appears to have built a significant moat around it's business to protect their excess profits, and has a long history of successfully keeping competitors at bay. (20+ years)

Per share earnings have quadrupled over that timeframe at a modest, but pretty consistent 7% annualized since 1995, plus BAX has an attractive history of buybacks and dividend increases. It seems highly likely that those trends will continue for the foreseeable future.

BAX seems to be what I would call an "all-star business", of significantly above average quality. And yet, BAX is selling for a below average price. (PE of 17.5 vs 18.6 for the S&P 500)

Therefore, I expect BAX to outperform the S&P 500 over the long-term.

Recs

0
Member Avatar Lippoldtskivich (38.57) Submitted: 11/5/2013 12:35:34 PM : Outperform Start Price: $33.52 BAX Score: +3.29

Broadly solid market positions for a profitable range of medical products, with aging populations in many countries and, currently, an expanding population covered by health insurance in the US. This is a relatively good situation.

Recs

0
Member Avatar benyboy (< 20) Submitted: 10/24/2013 2:55:17 AM : Outperform Start Price: $33.76 BAX Score: +1.35

Jimy cramer bullish on current levels $65

Recs

0
Member Avatar PeteH66 (< 20) Submitted: 10/7/2013 1:39:43 PM : Outperform Start Price: $33.21 BAX Score: -1.59

I buy the case (made here: http://seekingalpha.com/article/1726822-is-baxter-international-oversold-should-dividend-investors-be-taking-notice?source=email_investing_income&ifp=0) that Baxter is oversold in reaction to Biogen's intro of a competing blot-clot drug.

Recs

0
Member Avatar wtcrane1 (94.29) Submitted: 8/7/2013 3:15:54 PM : Outperform Start Price: $36.49 BAX Score: -10.94

undervalued, wide moat

Recs

0
Member Avatar Jolon (< 20) Submitted: 1/12/2013 10:12:24 PM : Outperform Start Price: $34.68 BAX Score: -23.26

Baxter has solid p/e and I predict it has a bright future ahead

Recs

0
Member Avatar olbar (< 20) Submitted: 12/10/2012 8:17:53 PM : Outperform Start Price: $37.45 BAX Score: +7.90

Baxter International Inc., moving to strengthen its already-substantial presence in the global kidney-dialysis market, disclosed Tuesday that it has agreed to pay about $4 billion to acquire Swedish dialysis equipment maker Gambro AB.

Recs

0
Member Avatar Marlonito9 (< 20) Submitted: 9/7/2012 9:44:38 PM : Underperform Start Price: $30.02 BAX Score: +8.27

It really should specially in the long run. It's inevitable due to natural market direction.

Recs

0
Member Avatar ryanman000 (< 20) Submitted: 4/13/2012 7:45:26 PM : Outperform Start Price: $27.37 BAX Score: -2.36

Watching this

Recs

0
Member Avatar campwt00global (32.88) Submitted: 9/6/2011 10:59:17 AM : Outperform Start Price: $25.45 BAX Score: -20.15

9/6/2011 BNY port rotate out of OXY to BAX 8/17/2011 at 53.51 can buy today at 52.48

Recs

0
Member Avatar ferdicemara (< 20) Submitted: 5/10/2011 8:33:52 AM : Outperform Start Price: $28.43 BAX Score: -10.42

SUCCESS

Recs

0
Member Avatar Covestor (60.61) Submitted: 3/14/2011 3:05:39 PM : Underperform Start Price: $25.08 BAX Score: -1.73

Covestor Model Manager SWAN-asset management sold BAX in his Christian Agape Hedged Equity Covestor Model ( http://covestor.com/SWAN-asset-management )

Recs

0
Member Avatar Chris5038 (< 20) Submitted: 2/7/2011 9:06:30 AM : Outperform Start Price: $23.24 BAX Score: +15.73

Buying new companies

Recs

1
Member Avatar thenatural24 (54.42) Submitted: 9/18/2010 9:09:10 AM : Outperform Start Price: $21.39 BAX Score: +5.42

I think this is a classic value play (and has a 2.5% dividend to boot). BAX has shown solid earnings growth and FCF, has a history repurchasing shares, and is, in my opinion, temporaily depressed due to a macro slowdown in protein plasma and antibody therapy. This presents a great buying opportunity.

Recs

0
Member Avatar jncgator (< 20) Submitted: 8/22/2010 12:27:41 PM : Underperform Start Price: $21.14 BAX Score: +0.37

This stock will eventually turn out in good shape from its recall on infusion pumps, but for now it should return to the 40 dollar per share range

Recs

0
Member Avatar falcon2382 (30.07) Submitted: 5/21/2010 11:27:21 PM : Outperform Start Price: $30.25 BAX Score: -61.70

Baxter was a shining star for me until April.... I'm going to pick some up in real life now that its dropped down to 40.... Does the market realize this is a Medical Technology conglomerate? And I know they cited the new Health Care Reform as an excuse as to why their revenues will be lower, but I don't get this. If EVERYONE get's insurance now, how does that negatively impact a medical technology supplier? Further, with Health Information Technology being one of the components of the required changes to healthcare, why not jump on that? Maybe the problem is management? Any thoughts? Any reason not to start nibbling at $40 a share?

Results 1 - 20 of 82 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement